INTEGRA LIFESCIENCES HOLDING (IART) Fundamental Analysis & Valuation

NASDAQ:IART • US4579852082

Current stock price

8.9 USD
-0.2 (-2.2%)
At close:
8.873 USD
-0.03 (-0.3%)
Pre-Market:

This IART fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. IART Profitability Analysis

1.1 Basic Checks

  • In the past year IART was profitable.
  • In the past year IART had a positive cash flow from operations.
  • In multiple years IART reported negative net income over the last 5 years.
  • IART had a positive operating cash flow in each of the past 5 years.
IART Yearly Net Income VS EBIT VS OCF VS FCFIART Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M -400M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -14.34%, IART is in line with its industry, outperforming 54.35% of the companies in the same industry.
  • IART's Return On Equity of -49.50% is in line compared to the rest of the industry. IART outperforms 50.00% of its industry peers.
  • IART's Return On Invested Capital of 4.34% is fine compared to the rest of the industry. IART outperforms 74.46% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for IART is below the industry average of 9.18%.
Industry RankSector Rank
ROA -14.34%
ROE -49.5%
ROIC 4.34%
ROA(3y)-4.24%
ROA(5y)-0.72%
ROE(3y)-15.23%
ROE(5y)-5.13%
ROIC(3y)5.05%
ROIC(5y)5.6%
IART Yearly ROA, ROE, ROICIART Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 -20 -30 -40

1.3 Margins

  • IART's Operating Margin of 10.58% is fine compared to the rest of the industry. IART outperforms 78.80% of its industry peers.
  • In the last couple of years the Operating Margin of IART has declined.
  • Looking at the Gross Margin, with a value of 56.62%, IART is in line with its industry, outperforming 56.52% of the companies in the same industry.
  • IART's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 10.58%
PM (TTM) N/A
GM 56.62%
OM growth 3Y-17.47%
OM growth 5Y-7.89%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.52%
GM growth 5Y-2.59%
IART Yearly Profit, Operating, Gross MarginsIART Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. IART Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so IART is destroying value.
  • The number of shares outstanding for IART has been increased compared to 1 year ago.
  • Compared to 5 years ago, IART has less shares outstanding
  • IART has a worse debt/assets ratio than last year.
IART Yearly Shares OutstandingIART Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
IART Yearly Total Debt VS Total AssetsIART Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

2.2 Solvency

  • Based on the Altman-Z score of 1.17, we must say that IART is in the distress zone and has some risk of bankruptcy.
  • IART has a Altman-Z score (1.17) which is comparable to the rest of the industry.
  • A Debt/Equity ratio of 1.66 is on the high side and indicates that IART has dependencies on debt financing.
  • IART has a Debt to Equity ratio of 1.66. This is amonst the worse of the industry: IART underperforms 80.98% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.66
Debt/FCF N/A
Altman-Z 1.17
ROIC/WACC0.63
WACC6.89%
IART Yearly LT Debt VS Equity VS FCFIART Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

2.3 Liquidity

  • IART has a Current Ratio of 2.54. This indicates that IART is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 2.54, IART perfoms like the industry average, outperforming 51.09% of the companies in the same industry.
  • A Quick Ratio of 1.46 indicates that IART should not have too much problems paying its short term obligations.
  • IART's Quick ratio of 1.46 is on the low side compared to the rest of the industry. IART is outperformed by 60.33% of its industry peers.
Industry RankSector Rank
Current Ratio 2.54
Quick Ratio 1.46
IART Yearly Current Assets VS Current LiabilitesIART Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. IART Growth Analysis

3.1 Past

  • IART shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.89%.
  • The Earnings Per Share has been decreasing by -1.86% on average over the past years.
  • The Revenue has been growing slightly by 1.53% in the past year.
  • IART shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.57% yearly.
EPS 1Y (TTM)-12.89%
EPS 3Y-12.69%
EPS 5Y-1.86%
EPS Q2Q%-14.43%
Revenue 1Y (TTM)1.53%
Revenue growth 3Y1.63%
Revenue growth 5Y3.57%
Sales Q2Q%-1.74%

3.2 Future

  • Based on estimates for the next years, IART will show a small growth in Earnings Per Share. The EPS will grow by 7.77% on average per year.
  • The Revenue is expected to grow by 2.86% on average over the next years.
EPS Next Y7.01%
EPS Next 2Y7.98%
EPS Next 3Y7.77%
EPS Next 5YN/A
Revenue Next Year2.71%
Revenue Next 2Y3.05%
Revenue Next 3Y2.86%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
IART Yearly Revenue VS EstimatesIART Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 500M 1B 1.5B
IART Yearly EPS VS EstimatesIART Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

7

4. IART Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 3.99, which indicates a rather cheap valuation of IART.
  • Compared to the rest of the industry, the Price/Earnings ratio of IART indicates a rather cheap valuation: IART is cheaper than 98.91% of the companies listed in the same industry.
  • When comparing the Price/Earnings ratio of IART to the average of the S&P500 Index (25.79), we can say IART is valued rather cheaply.
  • A Price/Forward Earnings ratio of 3.73 indicates a rather cheap valuation of IART.
  • Based on the Price/Forward Earnings ratio, IART is valued cheaper than 99.46% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of IART to the average of the S&P500 Index (23.80), we can say IART is valued rather cheaply.
Industry RankSector Rank
PE 3.99
Fwd PE 3.73
IART Price Earnings VS Forward Price EarningsIART Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of IART indicates a rather cheap valuation: IART is cheaper than 97.28% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 6.95
IART Per share dataIART EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.57
PEG (5Y)N/A
EPS Next 2Y7.98%
EPS Next 3Y7.77%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IART Dividend Analysis

5.1 Amount

  • No dividends for IART!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IART Fundamentals: All Metrics, Ratios and Statistics

INTEGRA LIFESCIENCES HOLDING

NASDAQ:IART (3/18/2026, 8:14:12 PM)

Premarket: 8.873 -0.03 (-0.3%)

8.9

-0.2 (-2.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-26
Earnings (Next)05-04
Inst Owners97.52%
Inst Owner Change1.22%
Ins Owners3%
Ins Owner Change-0.02%
Market Cap693.67M
Revenue(TTM)1.64B
Net Income(TTM)-516.47M
Analysts54.12
Price Target15.81 (77.64%)
Short Float %11.18%
Short Ratio9.81
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.69%
Min EPS beat(2)1.67%
Max EPS beat(2)21.7%
EPS beat(4)3
Avg EPS beat(4)4.71%
Min EPS beat(4)-6.76%
Max EPS beat(4)21.7%
EPS beat(8)5
Avg EPS beat(8)3.77%
EPS beat(12)6
Avg EPS beat(12)3.61%
EPS beat(16)9
Avg EPS beat(16)4.3%
Revenue beat(2)0
Avg Revenue beat(2)-2.8%
Min Revenue beat(2)-4.85%
Max Revenue beat(2)-0.75%
Revenue beat(4)1
Avg Revenue beat(4)-1.01%
Min Revenue beat(4)-4.85%
Max Revenue beat(4)3.14%
Revenue beat(8)1
Avg Revenue beat(8)-1.01%
Revenue beat(12)2
Avg Revenue beat(12)-1.1%
Revenue beat(16)3
Avg Revenue beat(16)-0.92%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-16.36%
EPS NQ rev (3m)-16.45%
EPS NY rev (1m)-0.48%
EPS NY rev (3m)-0.66%
Revenue NQ rev (1m)-2.62%
Revenue NQ rev (3m)-2.62%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 3.99
Fwd PE 3.73
P/S 0.42
P/FCF N/A
P/OCF 13.77
P/B 0.66
P/tB N/A
EV/EBITDA 6.95
EPS(TTM)2.23
EY25.06%
EPS(NY)2.39
Fwd EY26.81%
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)0.65
OCFY7.26%
SpS20.98
BVpS13.39
TBVpS-9.06
PEG (NY)0.57
PEG (5Y)N/A
Graham Number25.92
Profitability
Industry RankSector Rank
ROA -14.34%
ROE -49.5%
ROCE 5.5%
ROIC 4.34%
ROICexc 4.74%
ROICexgc 12.06%
OM 10.58%
PM (TTM) N/A
GM 56.62%
FCFM N/A
ROA(3y)-4.24%
ROA(5y)-0.72%
ROE(3y)-15.23%
ROE(5y)-5.13%
ROIC(3y)5.05%
ROIC(5y)5.6%
ROICexc(3y)5.53%
ROICexc(5y)6.31%
ROICexgc(3y)19.84%
ROICexgc(5y)22.5%
ROCE(3y)6.39%
ROCE(5y)7.09%
ROICexgc growth 3Y-20.99%
ROICexgc growth 5Y-10.51%
ROICexc growth 3Y-13.95%
ROICexc growth 5Y-5.53%
OM growth 3Y-17.47%
OM growth 5Y-7.89%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.52%
GM growth 5Y-2.59%
F-Score4
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 1.66
Debt/FCF N/A
Debt/EBITDA 5.33
Cap/Depr 62.99%
Cap/Sales 5.85%
Interest Coverage 2.12
Cash Conversion 15.51%
Profit Quality N/A
Current Ratio 2.54
Quick Ratio 1.46
Altman-Z 1.17
F-Score4
WACC6.89%
ROIC/WACC0.63
Cap/Depr(3y)66.1%
Cap/Depr(5y)55.65%
Cap/Sales(3y)5.76%
Cap/Sales(5y)4.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.89%
EPS 3Y-12.69%
EPS 5Y-1.86%
EPS Q2Q%-14.43%
EPS Next Y7.01%
EPS Next 2Y7.98%
EPS Next 3Y7.77%
EPS Next 5YN/A
Revenue 1Y (TTM)1.53%
Revenue growth 3Y1.63%
Revenue growth 5Y3.57%
Sales Q2Q%-1.74%
Revenue Next Year2.71%
Revenue Next 2Y3.05%
Revenue Next 3Y2.86%
Revenue Next 5YN/A
EBIT growth 1Y-5.3%
EBIT growth 3Y-16.12%
EBIT growth 5Y-4.59%
EBIT Next Year25.02%
EBIT Next 3Y12.61%
EBIT Next 5YN/A
FCF growth 1Y-401.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-61.06%
OCF growth 3Y-42.46%
OCF growth 5Y-24.38%

INTEGRA LIFESCIENCES HOLDING / IART Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for INTEGRA LIFESCIENCES HOLDING?

ChartMill assigns a fundamental rating of 3 / 10 to IART.


What is the valuation status for IART stock?

ChartMill assigns a valuation rating of 7 / 10 to INTEGRA LIFESCIENCES HOLDING (IART). This can be considered as Undervalued.


What is the profitability of IART stock?

INTEGRA LIFESCIENCES HOLDING (IART) has a profitability rating of 3 / 10.


What is the financial health of INTEGRA LIFESCIENCES HOLDING (IART) stock?

The financial health rating of INTEGRA LIFESCIENCES HOLDING (IART) is 2 / 10.